Vascular endothelial growth factor fusion constructs used to...

Details Vascular endothelial growth factor fusion constructs used to... Vascular endothelial growth factor fusion constructs used to...

2004-08-16

2009-10-13

Saoud, Christine J (Department: 1647)

Drug, bio-affecting and body treating compositions

Lymphokine

C424S085200, C424S094630, C514S002600, C514S012200, C530S351000, C530S399000

Reexamination Certificate

active

07601341

ABSTRACT:
The 121-amino acid isoform of vascular endothelial growth factor (VEGF121) is linked by a flexible G4S tether to a cytotoxic molecule such as toxin gelonin or granzyme B and expressed as a soluble fusion protein. The VEGF121, fusion protein exhibits significant anti-tumor vascular-ablative effects that inhibit the growth of primary tumors and inhibit metastatic spread and vascularization of metastases. The VEGF121fusion protein also target osteoclast precursor cells in vivo and inhibits osteoclastogenesis.

REFERENCES:
patent: 5219739 (1993-06-01), Tisher et al.
patent: 5889155 (1999-03-01), Ashkenazi et al.
patent: 5994104 (1999-11-01), Anderson et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6451312 (2002-09-01), Thorpe
patent: 6692724 (2004-02-01), Yang et al.
patent: 7067111 (2006-06-01), Yang et al.
patent: 7229604 (2007-06-01), Yang et al.
patent: 2002/0114783 (2002-08-01), Appukuttan et al.
patent: 2003/0040496 (2003-02-01), Chandler et al.
patent: 2003/0082159 (2003-05-01), Appukuttan et al.
patent: 2003/0086919 (2003-05-01), Rosenblum et al.
patent: 2004/0166058 (2004-08-01), Yang et al.
patent: 2004/0248805 (2004-12-01), Rosenblum
patent: 2005/0024380 (2005-02-01), Lin et al.
patent: 2005/0037967 (2005-02-01), Rosenblum
patent: 2005/0129619 (2005-06-01), Yang et al.
patent: 2006/0134810 (2006-06-01), Bullock
patent: 1506787 (2005-02-01), None
patent: WO 90/13649 (1990-11-01), None
patent: WO 96/06641 (1996-03-01), None
patent: WO 02/083851 (2002-10-01), None
patent: WO 2004/108074 (2004-12-01), None
patent: WO 2006/031353 (2006-03-01), None
Deckers et al. Endocrinology 141(5): 1667-1674, 2000.
Pufe et al. Bone 33: 869-876, 2003.
Cheung et al. Proc. Am. Assoc. Can. Res. 41: 387, 2000 (#2458).
Kong et al. Molecular control of bone remodeling and osteoporosis. Experimental Gerontology 35: 947-956, 2000.
Takayanagi et al. Biochem. Biophys. Res. Comm. 240: 279-286, 1997.
Street et al. PNAS 99(15): 9656-9661, 2002.
Cheung et al. #2458. In vitro and in vivo studies of VEGF121/RGEL fusion toxin targeting tumor neovasculature. Proc. Am. Assoc. Cancer Res. 41: 387, Mar. 2000.
Kreitman et al. Immunotoxins for targeted cancer therapy. Advanced Drug Delivery Reviews 31: 53-88, 1998.
Engsig et al. J. Cell Biol. 151(4): 879-889, 2000.
Ferrara Endocrine Reviews 25(4): 581-611, 2004.
Arora et al. Cancer research 59: 183-188, 1999.
Liu et al., “Mechanistic studies of a novel human fusion toxin composed of vascular endothelial growth factor (VEGF)121 and the serine protease granzyme B: directed apoptotic events in vascular endothelial cells,”Mol. Cancer Therapeutics, 2:949-959, 2003.
Veenendaal et al., “In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors,”Proc. Natl. Acad. Sci. USA, 99:7866-7871, 2002.
Murata et al., “Combrastatin A-4 disodium phosphate: a vascular targeting agent that improves the anti-tumor effects of hyperthermia, radiation, and mild thermotherapy,”Int. J. Radiation Oncology Biol. Phys., 51:1081-1024, 2001.
Wild et al., “Inhibition of angiogenesis and tumor growth by VEGF121-toxin conjugate: differential effect on proliferating endothelial cells,”Br. J. Cancer, 83:1077-1083, 2000.
Arora et al., “Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells,”Cancer Res., 59:183-188, 1999.
Cheung et al., “In vitro and in vivo studies of VEGF121/RGEL fusion toxin targeting tumor neovasculature,”Proc. Am. Assoc. Cancer Res., 41:387, 2000 (Abstract No. 2458).
Gerber et al., “Andiogenesis and Bone Growth,”TCM, 10:223-228, 2000.
Kreitman et al., “Immunotoxins for targeted cancer therapy,”Adv. Drug Delivery Rev., 31:53-88, 1998.
Rosenblum et al., “Recombinant immunotoxins directed against the c-erb-2/HER2
eu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models,”Clin. Cancer Res., 5:865-874, 1999.
Smyth et al., “Granzymes: exogenous proteinases that induce target cell apoptosis,”Immunology Today, 16: 202-206, 1995.
Adamis et al., “Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy,”Am. J. Opthalmol., 118:445-450, 1994.
Adamis et al., “Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate,”Arch. Ophthalmol., 114:66-71, 1996.
Aiello et al., “Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins,”Proc. Natl. Acad. Sci. USA, 92:10457-10461, 1995.
Aiello et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders,”N. Engl. J. Med., 331:1480-1487, 1994.
Anand-Apte et al., “A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth,”Biochem. Cell. Biol., 74:853-862, 1996.
Bergers et al., “Effects of Angiogenesis Inhibitors of Multistage Carcinogenesis of Mice,”Science, 284:808-812, 1999.
Bhisitkul et al., “An antisense oligodeoxynucleotide against vascular endothelial growth factor in a nonhuman primate model of iris neovascularization,”Arch Ophthalmol, 123:214-219, 2005.
Bigg et al., “Specific, high affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-terminal hemopexin-like domain of human gelatinase A. TIMP-4 binds progelatinase A and the COOH-terminal domain in a similar manner to TIMP-2,”J. Biol. Chem., 272:15496-15500, 1997.
Bird et al., “Single-Chain Antigen-Binding Proteins,”Science, 242:423-426, 1988.
Boehm et al., “Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance,”Nature, 390:404-407, 1997.
Brinkmann and Pastan, “Immunotoxins against cancer,”Biochim. Biophys. Acta, 1198(1):27-45, 1994.
Brooks et al., “Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone,”Arch Ophthalmol, 122:1801-1807, 2004.
Burbage et al., “Ricin fusion toxin targeted to the human granulocyte-macrophage colony stimulating factor receptor is selectively toxic to acute myeloid leukemia cells,”Leuk Res., 21(7):681-690, 1997.
Cao et al., “Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth,”J. Biol. Chem., 272: 22924-22928, 1997.
Chaudhary et al., “A rapid method of cloning functional variable-region antibody genes inEscherichia colias single-chain immunotoxins,”Proc. Natl. Acad. Sci. USA, 87(3):1066-1070, 1990.
Denekamp, “The tumour microcirculation as a target in cancer therapy: a clearer perspective,”Eur. J. Clin. Invest., 29:733-736, 1999.
Endo et al., “Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy,”Horm Metab Res, 33:317-322, 2001.
Funatsu et al., “Risk evaluation of outcome of vitreous surgery for proliferative diabetic retinopathy based on vitreous level of vascular endothelial growth factor and angiotensin II,”Br J Ophthalmol, 88:1064-1068, 2004.
Gan et al., “Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing,”Acta Ophthalmol Scand., 82:557-563, 2004.
Gaudreault et al., “Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration,”Invest Ophthalmol Vis Sci, 46:726-733, 2005.
Gomez et al., “Tissue inhibitors of metalloproteinases: structure, regulation and biological functions,”Eur. J. Cell. Biol

Affiliated with

Also associated with

Rating

Vascular endothelial growth factor fusion constructs used to... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vascular endothelial growth factor fusion constructs used to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vascular endothelial growth factor fusion constructs used to... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4143272